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Background: Alzheimer's disease (AD) is a devastating condition with no known effective drug treatments.
Existing drugs only alleviate symptoms. Given repeated expensive drug failures, we assessed systematically
whether approved and investigational AD drugs are targeting products of genes strongly associated with AD
and whether these genes are targeted by existing drugs for other indications which could be re-purposed.
Methods:We identified genes strongly associated with late-onset AD from the loci of genetic variants associated
with AD at genome-wide-significance and from a gene-based test applied to the most extensively genotyped
late-onset AD case (n= 17,008)-control (n=37,154) study, the International Genomics of Alzheimer's Project.
We used three gene-to-drug cross-references, Kyoto Encyclopedia of Genes and Genomes, Drugbank and Drug
Repurposing Hub, to identify genetically validated targets of AD drugs and any existing drugs or nutraceuticals
targeting products of the genes strongly associated with late-onset AD.
Findings:A total of 67 autosomal genes (forming 9 gene clusters)were identified as strongly associatedwith late-
onset AD, 28 from the loci of single genetic variants, 51 from the gene-based test and 12 by both methods.
Existing approved or investigational AD drugs did not target products of any of these 67 genes. Drugs for other
indications targeted 11 of these genes, including immunosuppressive disease-modifying anti-rheumatic drugs
targeting PTK2B gene products.
Interpretation: Approved and investigational AD drugs are not targeting products of genes strongly associated
with late-onset AD. However, other drugs targeting products of these genes exist and could perhaps be re-
purposing to combat late-onset AD after further scrutiny.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Alzheimer's disease (AD) has remained incurable since its first dis-
covery in 1906 [1]. An estimated one-third of AD cases may be associ-
ated with lifestyle or related attributes, education and other health
conditions (hypertension, obesity, diabetes, depression) [2], although
the exact interventions require clarification [3]. Mendelian randomiza-
tion studies using single nucleotide polymorphisms (SNPs) as instru-
ments suggest that apolipoprotein E, systolic blood pressure, smoking
and vitamin D are inversely associated with AD [4–6]. Effective thera-
pies to prevent and treat ADwere called for globally at the G8 dementia
summit in 2013 [7], because of the escalating societal costs if AD re-
mains untreated [8]. Effective drug treatments for AD have proved
elusive.
Current understanding of AD is based on factors identified from
brain autopsies, which in 1976 implicated acetylcholine, “the
EBioMedicine 37 (2018) 461–470
⁎ Corresponding author at: School of Public Health, Li Ka Shing Faculty of Medicine, The
University of Hong Kong, 1/F, Patrick Manson Building (North Wing), 7 Sassoon Road,
Hong Kong, China.
E-mail address: cms1@hku.hk (C.M. Schooling).
https://doi.org/10.1016/j.ebiom.2018.10.001
2352-3964/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.com
cholinergic hypothesis” [9,10], and subsequently implicated beta-
amyloid (Aβ) in extracellular plaques in 1984 and tau proteins in
neurofibrillary tangles in 1986 [11]. Drug development based on
these hypotheses has yielded two types of drugs for AD approved
by the U.S. Food and Drug Administration (FDA), including cholines-
terase inhibitors, N-methyl-D-aspartate receptor antagonists, and
the combination of these inhibitors. These drugs relieve symptoms
rather than delaying progression. No new AD drugs have been ap-
proved by the U.S. FDA since 2003, despite over 400 trials from
2002 to 2012 mainly targeting Aβ [12]. These difficulties may be
due to lack of pre-trial biomarker screening to identify high risk pa-
tients as selection criteria [13], or use of subjectively rated cognitive
and functional outcomes rather than validated biomarkers [14].
However, failure of anti-Aβ drugs has raised questions about the
causal role of amyloid protein in AD and the relevance of the amyloid
protein hypothesis to AD drug development [15,16]. In vitro studies
suggest Aβ and its precursor amyloid protein precursor are damage
response proteins [17] so amyloid plaque may be a consequence
rather than a cause [18]. More importantly, both Aβ and tau protein
may not only be neurotoxins, but also be relevant to normal physio-
logical functions [15].
In response to issues with drug development, genetic validation
of drug targets is becoming increasing popular, and has recently ex-
plained the failure of several cardiovascular drugs, such as
darapladib and varespladib, where functionally relevant genetic var-
iants were found relevant to the drug but not to the disease [19,20].
However, overall a small number of drug identified from SNP-based
genome-wide association studies (GWAS) have raised the concerns
that GWAS may fail to identify causal SNPs by excluding SNPs with
greater effect but low frequency [21]. To identify new targets for
the most common form of AD, i.e., late (65+ years)-onset AD
agnostically, we considered genetic variation in naturally occurring
functional units, i.e., genes, as an initial step. A previous gene-based
study of people of European ancestry in the International Genomics
of Alzheimer's Project (IGAP) found 13 genes known from genetic
loci of SNPs identified in GWAS, 3 genes in close proximity to 2
known genes and 2 new genes (TP53INP1, IGHV1–67) [22]. Another
gene-based study of AD in a trans-ethnic GWAS of people of
European, African-Americans, Japanese and Israeli-Arabs ancestry
replicated 7 known genes and identified 1 new gene (TPBG) [23].
However, these studies did not compare late-onset AD gene products
with targets of AD drugs. To our knowledge, only one previous study
has compared AD genetic loci with targets of approved AD drugs
[21]. Here, we build on this previous work by firstly identifying
genes associated with specifically late-onset AD from a gene-based
test and from the loci of SNPs found in previous GWAS, secondly
assessing the overlap between these late-onset AD gene products
and targets of currently approved or investigational AD drugs, and
thirdly identifying any other existing drugs or nutraceuticals
targeting products of these late-onset AD genes that could poten-
tially be re-purposed to prevent or treat AD. Given genes from
GWAS have been shown to be more likely to be drug targets than
random genes for complex traits [24] or heritable diseases [25], our
findings of any discrepancy between products of these AD genes
and drug targets would indicate opportunities for using AD genes
for drug discovery and repurposing. Conversely, genes without
even a nominal association with late-onset AD might be screened
out and de-prioritized as indicators of potential targets of
intervention.
2. Materials and methods
2.1. Genes associated with AD
We obtained genes strongly associated with late-onset AD using
two approaches. First, we ascertained AD genes from all loci of single
nucleotide polymorphisms (SNPs) associated with late-onset AD at
genome wide significance in a recent review of GWAS [26]
(i.e., SNP-based GWAS). In addition, we did not use the Online
Research in context
Evidence before this study
We searched PubMed for articles on Alzheimer's disease (AD)
published between January 1, 1960 and August 28, 2018 using
the terms: (“Alzheimer's disease” AND genetics AND GWAS) to
identifyADgenes; and (“Alzheimer's disease”AND “drug therapy”)
to identify AD treatments.We screened articles by title and abstract
to locate full-text articles relevant to the study aims, supplemented
by reference lists of the relevant articles.Weconsidered articles that
examined the associations of genetic variants or genes with late-
onset AD, or evaluated existing or investigational AD drugs. AD
drug development has encountered limited efficacy of existing
drugs and repeated expensive failures of investigational drugs. Ge-
netic validation of drug targets may provide the impetus to rethink
effective drug treatments for late-onsetAD.Genetic variants related
to late-onset AD have been extensively identified from genome-
wide association studies (GWAS); however, late-onset AD genes,
rather than loci, are less studied. Only two gene-based studies of
late-onset AD have been published. One study in people of
European ancestry found two new genes and one trans-ethnic
study found another new gene. However, none of these gene-
based studies comparedwithADdrug targets.Only one study com-
pared genetic loci from previous GWAS with targets of approved
AD drugs and found no overlaps. No studies have considered
whether products of late-onset AD genes are targets of numerous
on-going investigational AD drugs or whether any late-onset AD
gene products are targeted by drugs for other indications.
Added value of this study
We revisited the late-onset ADgenesof European ancestry using a
new gene-based association analysis and compared them with
known late-onset AD genes indicated by loci from previous
GWAS.We then compared all these late-onset AD gene products
with targets of currently approved or investigational AD drugs and
identified drugs for other indications targeting any late-onset AD
gene products. This gene-based association analysis of late-
onset AD replicated 12 genes found by previous GWAS and addi-
tionally identified 39 genes.We did not replicate 3 genes found by
the two previous gene-based studies, perhaps partly due to
population-specific relevance of particular genes. Moreover, this
study found no evidence that approved AD drugs or AD drugs in
Phase III trials are targeting the products of genes strongly associ-
atedwith late-onset AD, consistentwith a previous study compar-
ing AD genetic loci with approved AD drugs, although false
negative findings due to incomplete knowledge remains possible.
Among all 67 late-onsetADgenes from this gene-based study and
previous GWAS, 11 genes are targets of other existing drugs,
which could possibly be further scrutinized for appropriate align-
ment of disease genetics and drug actions before re-purposing.
Implications of all the available evidence
This study forms an initial step in translating genetic evidence to
AD drug development. It also highlights the importance of genetic
validation of investigational AD drugs as an initial screening tool to
identify promising late-onset AD drug.
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Mendelian Inheritance in Man (OMIM) because no additional genes
associated with late-onset AD reaching genome-wide Bonferroni
corrected significance could be identified. Second, we ascertained
AD genes as genes associated with AD at Bonferroni corrected signif-
icance using a gene-based test applied to the largest, most densely
genotyped (7,055,881 SNPs genotyped or imputed in autosomal
chromosomes using the 1000 Genomes catalog) case (n = 17,008)-
control (n = 37,154) study of AD, stage 1 discovery sample from
the IGAP, in people of European descent (mean age 71.4 years) ad-
justed for age and sex and corrected for population stratification
[27]. Among all these late-onset AD genes, we then obtained gene
clusters based on two or more genes that encode for similar proteins
within the same gene family classified by the HUGO Gene Nomencla-
ture Committee (HGNC) [28].
2.2. Therapies targeting identified genes
To assess whether existing AD drugs are targeting products of
late-onset AD genes and whether genes strongly associated with
AD are being fully exploited, two researchers independently identi-
fied the genes targeted by AD drugs using three gene-to-drug
cross-references, Kyoto Encyclopedia of Genes and Genomes
(KEGG) [29], Drugbank [30], and Drug Repurposing Hub [31] as of
August 30, 2018. For existing AD drugs, in KEGG, we searched each
drug on “KEGG Drug” and identified the targets given in the “Target
pathway”. In Drugbank, we searched for each drug by specifying
“Drugs”, and identified the targets based on “Targets: Gene Name”.
In Drug Repurposing Hub, we searched each drug by specifying
“Name:” and identified the targets based on the “Target”. To identify
treatments targeting AD genes, in KEGG, we searched each gene on
“KEGG Disease” and identified the treatments for that particular
gene as listed in “Gene” given in the “Drug target”. In Drugbank, we
searched for each gene by specifying “Targets”, and identified the
treatments based on “Drug relations” (including drugs labeled as
“approved” with known pharmacological action). In Drug
Repurposing Hub, we searched each gene by specifying “Target:”
and identified the treatments based on the “Name” (including
drugs labeled as “Launched” phase). We considered all existing or in-
vestigational AD drugs. The list of investigational drugs was based on
drugs being tested in recruiting or active Phase III or IV trials regis-
tered in ClinicalTrial.gov or listed in AlzForum (http://www.
alzforum.org/therapeutics) as of January 28, 2018, supplemented
by drugs in Phase III trials listed in Cummings J, et al. (2016) [32], ex-
cluding diagnostic drugs and drugs for sequelae of AD, such as for ag-
itation or sleep disorders.
2.3. Statistical analysis
Weobtained an overall P-value for the association of each autosomal
genewith late-onset AD by combining P-values for the association of all
the SNPs within each gene using GATES accounted for linkage disequi-
librium between loci [33]. GATES has the advantage of not requiring
permutations or simulations, and maintains a Type I error (false posi-
tive) rate regardless of gene size or linkage disequilibrium patterns
among SNPs. We only considered genes reaching genome-wide
Bonferroni corrected significance (nominal P-valueb.000002, i.e., .05/
25000 genes) such that genes identified from this gene-based test are
selected on the same basis as genes identified from SNP-based GWAS
[26]. We performed a hypergeometric test to obtain the probability of
the identified genes being targeted by AD drug or drugs for other indi-
cations, assuming 5% of the human genomes (same as the significance
level of one-tailed Fisher test) are targeted by AD drugs or drugs for
other indications (n = 1250 genes) and the remaining genes are not
targeted. This analysis of publicly available data does not require ethical
approval.
3. Results
Table 1 shows that 28 genes strongly associated with AD were
identified from the SNP-based GWAS [26] and 51 from the gene-
based test, with 12 genes (APOE, CLU, BIN1, CR1, PICALM, MS4A6A,
EPHA1, SORL1, ABCA7, PTK2B, CD33, CD2AP) identified by both ap-
proaches. A total of 16 genes (SLC24A4-RIN3, CELF1, CASS4, TRIP4,
ZCWPW1, HLA-DRB5-HLA-DRB1, FERMT2, NME8, INPP5D, TREM2,
TREML2, MEF2C, ACE, APP, PLD3, DSG2) were only identified from
the SNP-based GWAS, and 39 genes (including 2 pseudogenes:
APOC1P1, CEACAM22P) were only identified from the gene-based
test. Most of these 67 genes (n = 33) were on chromosome 19,
where all 4 genes with the smallest P-value (APOC1, APOE, NECTIN2,
TOMM40) are located. When considering these 67 genes together, 9
gene clusters were identified including apolipoproteins (APOC1,
APOE, APOC2, APOC4, APOC4-APOC2), carcinoembryonic antigen re-
lated cell adhesion molecule (CEACAM16, CEACAM19), cluster of dif-
ferentiationmolecule (ACE, CD33, CD2AP), complement system (CR1,
CR1L), ephrins (EPHA1, EPHA1-AS1), histocompatibility complex
(HLA-DQA1, HLA-DRB5-HLA-DRB1), membrane spanning 4-domains
(MS4A6E, MS4A4A, MS4A6A, MS4A4E, MS4A2), microRNAs
(MIR6843, MIR6503, MIR4531) and V-set domain containing
(TREM2, TREML2). As such, in addition to identifying the same 12
genes and 7 gene clusters as previous SNP-based GWAS, this gene-
based test newly identified 39 genes (of which 4 genes were in
strong linkage disequilibrium with previously known genes) and 2
gene clusters (CEACAM, MIR) (formed from 5 genes).
The current approved or investigational AD drugs did not target
products of any of these 67 genes strongly associated with AD
(Table 2). However, drugs for other indications targeted products
of 11 of the 67 late-onset AD genes, with P-value = .0001 which in-
dicates our results unlikely occurred by chance. These other drugs
targeting products of these 11 genes (ACE, APP, APOE, CD33, CLU,
EPHA1, HBEGF, HLA-DQA1, HLA-DRB1, MS4A2, PTK2B) including
Gemtuzumab ozogamicin which targets CD33 gene products,
Omalizumab which targets MS4A2 gene products and Baricitinib/
Fostamatinib/Leflunomide which targets PTK2B gene products
(Table 3).
4. Discussion
Among the 67 genes found strongly associated with late-onset AD,
this gene-based study replicated 12 genes and 7 gene clusters found
by previous SNP-based GWAS and identified 39 new genes (of which
4 genes were in strong linkage disequilibrium with previously known
genes) and 2 new gene clusters (formed from 5 genes). However, we
did not replicate 3 genes (TP53INP1, IGHV1–67, TPBG) found by previous
gene-based studies, possibly because the study of people of European
ancestry in IGAP used Fisher's combination test [22], which is prone to
type 1 error [33], and the trans-ethnic GWAS using the same GATES
method may have identified population-specific genes [23]. Moreover,
our study suggests existing AD drugs (cholinesterase inhibitors or N-
methyl-D-aspartate receptor antagonists) may not be targeting prod-
ucts of these late-onset AD genes, consistent with the previous compar-
ison of AD genetic loci with approved AD drugs [21].We also found that
existing investigational AD drugs currently in Phase III trials (anti-Aβ
agents, anti-tau agents, other neurotransmitters agonist/antagonists
and insulin sensitizers) did not appear to be targeting products of
late-onset AD genes.We cannot rule out the possibility that incomplete
knowledge of AD genes and/or drug targets could generate such null
findings. Finally, we found products of 11 AD genes are targets of
existing drugs for other indications, which could possibly be considered
for further scrutiny of directionality of disease genetics and drug actions
within an integrated biological networks before re-purposing to miti-
gate or cure late-onset AD.
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Our study suggests a ‘mismatch’ between approved or investi-
gational AD drugs and the genes strongly related to late-onset AD.
Cholinesterase inhibitors are not the only neurotransmitter related
to AD [11] and may have missed the window of intervention in
late-onset AD because of the accumulated loss of neurological func-
tions [13]. N-methyl-D-aspartate receptor antagonists aim to op-
pose the effects of the excitatory neurotransmitter glutamate
[34], however the causal role of glutamate in AD is yet to be eluci-
dated [35]. The investigational drugs are mainly anti-Aβ and anti-
tau agents, which are not known to target products of genes associ-
ated with late-onset AD, but are largely based on causal
associations with familial AD. Aβ is the product of the APP gene
which is primarily associated with early-onset AD [36] except for
a rare genetic variant [37]. The latest failures of these drug classes
in late-onset AD [38,39], have raised questions as to whether Aβ
and tau proteins are biomarkers [15] or underlying causal targets
[18]. The exact reasons for such an exceptionally high failure rate
remains elusive, but several explanations have been proposed in-
cluding: anti-Aβ trials have not reported changes in cerebrospinal
fluid Aβ [40], results from animal models may not be comparable
to human trials [41], clearance of existing Aβ protein may be as im-
portant as reduction in Aβ generation [42], and off-target pathways
Table 1
Genes associated with late-onset Alzheimer's diseasea identified from gene-based association test and/or single nucleotide polymorphism (SNP)-based genome-wide association studies
(GWAS).
Chromosome Gene-based test + SNP-based GWAS Gene-based testb SNP-based GWAS
Position Gene P-value Position Gene P-value Position Gene P-value
1 207,669,472 CR1 2.25 × 10−13 207,818,457 CR1L 3.01 × 10−08
2 127,805,598 BIN1 2.86 × 10−14 234,068,476 INPP5D 1.21 × 10−03
5 139,712,427 HBEGF 1.83 × 10−06 88,223,420 MEF2C 0.01
6 47,445,524 CD2AP 1.76 × 10−06 32,605,182 HLA-DQA1 9.36 × 10−07 32,578,530 HLA-DRB5-HLA-DRB1 8.77 × 10−05
41,129,252 TREM2 5.09 × 10−03
41,154,650 TREML2 9.98 × 10−03
7 143,088,204 EPHA1 7.57 × 10−10 143,104,905 EPHA1-AS1 1.92 × 10−09 100,004,446 ZCWPW1 8.56 × 10−05
37,841,534 NME8 3.70 × 10−04
8 27,454,433 CLU 5.91 × 10−16 27,468,117 MIR6843 6.39 × 10−16
27,183,080 PTK2B 3.66 × 10−07
11 85,668,213 PICALM 9.31 × 10−11 60,102,354 MS4A6E 9.71 × 10−12 47,557,871 CELF1 2.90 × 10−05
59,939,970 MS4A6A 6.24 × 10−10 60,048,013 MS4A4A 1.04 × 10−10
121,322,911 SORL1 5.25 × 10−09 59,968,725 MS4A4E 1.59 × 10−09
59,976,543 MIR6503 1.76 × 10−09
59,856,136 MS4A2 4.47 × 10−09
14 92,926,952 SLC24A4-RIN3 6.71 × 10−06
53,400,629 FERMT2 3.50 × 10−04
15 64,725,490 TRIP4 4.79 × 10−05
17 61,538,148 ACE 0.01
18 29,088,958 DSG2 0.98
19 45,409,657 APOE 0 45,417,811 APOC1 0 40,877,595 PLD3 0.90
1,040,101 ABCA7 2.12 × 10−07 45,430,059 APOC1P1 0
51,728,334 CD33 8.09 × 10−07 45,349,392 NECTIN2 0
45,394,476 TOMM40 0
45,312,315 BCAM 7.50 × 10−68
45,281,125 CBLC 3.09 × 10−42
45,251,977 BCL3 9.04 × 10−42
45,653,007 NKPD1 5.26 × 10−20
45,458,480 CLPTM1 5.75 × 10−20
45,596,430 PPP1R37 8.07 × 10−20
45,666,185 TRAPPC6A 2.78 × 10−18
45,682,002 BLOC1S3 2.78 × 10−17
45,504,706 RELB 5.31 × 10−17
45,449,238 APOC2 6.67 × 10−16
45,542,297 CLASRP 1.13 × 10−15
45,445,494 APOC4 2.91 × 10−15
45,445,494 APOC4-APOC2 3.38 × 10−15
45,715,634 EXOC3L2 9.26 × 10−14
45,147,097 PVR 2.53 × 10−12
45,588,586 LOC105372419 9.04 × 10−12
45,583,162 GEMIN7 1.17 × 10−11
45,202,420 CEACAM16 3.97 × 10−11
45,174,723 CEACAM19 1.58 × 10−09
45,156,955 MIR4531 3.97 × 10−09
45,116,939 IGSF23 4.25 × 10−08
1,076,632 ARHGAP45 8.21 × 10−08
45,041,044 CEACAM22P 9.34 × 10−08
46,213,886 FBXO46 1.23 × 10−06
46,236,508 BHMG1 1.30 × 10−06
20 55,018,260 CASS4 3.60 × 10−05
21 27,269,932 APP 0.08
Abbreviations: GWAS: genome wide association studies; SNPs: single nucleotide polymorphisms.
a All gene P-values were based on gene-based association test.
b Among the 39 genes newly identified from the gene-based test, 4 genes were in strong linkage disequilibriumwith previously known genes (previous gene vs. new genewith r2: CLU
vs.MIR6843 (0.875);MS4A6A vs.MS4A2 (0.844);MS4A6A vs.MIR6503 (0.844) and ABCA7 vs. ARHGAP45 (0.967).
464 M.K. Kwok et al. / EBioMedicine 37 (2018) 461–470
Table 2
Genes with products targeteda by approved or investigational Alzheimer's disease drugsb.
Type Drug Target Gene Gene
P-value
Class
Approved drugs Donepezil ACHE 0.65 Acetylcholinesterase inhibitor
HTR2A 0.03
Rivastigmine ACHE
BCHE
0.65
0.73
Acetylcholinesterase inhibitor
Galantamine ACHE 0.65 Acetylcholinesterase inhibitor
CHRNA1-A8;A10 0.22
CHRNB1-B4 0.77
CHRND 0.89
CHRNE 0.0003
CHRNG 0.58
BCHE 0.73
Memantine CHRNA7
CYP2E1
DRD2
GRIN1
GRIN2A/2B
GRIN3A
HTR3A
0.72
0.94
0.23
0.97
0.50
0.85
0.24
N-methyl-D-aspartate receptor antagonist
Investigational drugs Aducanumab Nil – Anti-amyloid
ALZT-OP1a/b ASIC1
BCL2
CFTR
FABP2
KCNMA1
S100P
SLC15A1/A8
PLAT
PPARA
PPARG
PTGS1/2
THBD
0.28
0.56
0.98
0.99
0.59
0.22
0.40
0.57
0.97
0.98
0.43
0.44
Anti-amyloid
Anti-inflammation
Azeliragon AGER 0.13 Anti-amyloid
Anti-inflammation
CNP520 Nil – Anti-amyloid
Crenezumab Nil – Anti-amyloid
Elenbecestat Nil – Anti-amyloid
Gantenerumab Nil – Anti-amyloid
JNJ-54861911 Nil – Anti-amyloid
Pioglitazone INS
PPARA
PPARD
PPARG
TRPM3
MAOB
0.97
0.97
0.50
0.72
0.27
--
Insulin sensitizer
Anti-inflammation
Intepirdine Nil – Other neurotransmitters (Selective serotonin 5-HT₆ receptor antagonist)
Solanezumab Nil – Anti-amyloid
TRx0237 Nil – Anti-tau
Verubecestat BACE1 – Anti-amyloid
Guanfacine ADRA2A-2C
CYP3A5
HCN1/4
0.16
0.38
0.62
Other neurotransmitters (Attention Deficit Hyperactivity Disorder drug)
Insulin
(Humulin®RU-10)
INSR
IGF1R
RB1
CTSD
IDE
PCSK1/2
CPE
NOV
LRP2
IGFBP7
SYTL4
0.83
0.78
0.26
0.11
0.45
0.41
0.09
0.30
0.40
0.70
--
Intranasal insulin
Lanabecestat Nil – Anti-amyloid
Sodium oligomannurarate Nil – Anti-amyloid (Oligosaccharide)
Docosahexaenoic acid PPARA
PPARG
RXRA
RXRB
RXRG
SREBF1
0.97
0.72
0.25
0.86
0.13
0.58
Other (Unsaturated fatty acid synthesis)
Tricaprilin Nil – Other (triacylglycerols)
Lithium Carbonate GSK3B
IMPA1/2
GRIA3
0.98
0.04
--
Other (alkali metal compounds)
(continued on next page)
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that induce adverse effects might negate the possible benefits of Aβ
accumulation. Notably, the possibility of citation bias in favour of
the beta-amyloid hypothesis for AD has been raised [43].
We identified 67 genes strongly associated with late-onset AD
(12 genes from both approaches, 16 from SNP-based GWAS and 39
from the gene-based test). The 12 genes identified by both ap-
proaches relate to lipid metabolism or transport (e.g. APOE, SORL1,
ABCA7), synaptic function (BIN1, PICALM, MA4A6A, PTK2B), immune
response (CR1, CD33, CD2AP) or cell proliferation or apoptosis (CLU,
EPHA1) [44]. With replication by the gene-based test of findings
from previous SNP-based GWAS, products of these 12 genes could
possibly be potential drug targets. Conversely, 16 genes inferred
from previous SNP-based GWAS as associated with late-onset AD
were not associated with AD on the gene-based test, perhaps indicat-
ing that these SNPs might not indicate causal genes [27]. As such,
considering genetic variants in functional units, i.e., genes, as here
may be informative, in addition to considering single genetic vari-
ants. For genes with variants representing loss-of-function, drugs
that activate (agonists) proteins in human cells would be needed,
whereas drugs that inhibit (antagonists) would be needed for vari-
ants representing gain-of-function [25]. Understanding AD patho-
genesis and drug actions are necessary for translating our genetic
validations into identification of therapeutic targets.
Other identified genes, if substantiated by future studies with
clearly defined disease genetics and drug actions, could provide
new, promising directions for late-onset AD therapeutic investiga-
tion. For example, NECTIN2 relates to cell-to-cell spreading of the
herpes simplex virus and pseudorabies virus, when herpes simplex
virus type 1 is thought to play a role in AD [45]. A recent drug trial
targeting the virus (VALZ-PILOT) has been launched, although it is
not known to target products of the 67 identified late-onset AD
genes [46]. Further, the 9 gene clusters identified by the gene-
based test and/or SNP-based GWAS could be potentially relevant
genetic loci implicated in late-onset AD. The APO gene cluster (lipo-
protein metabolism) consistently identified by both approaches
may play a causal role. Particularly the APOE gene, as substantiated
Table 2 (continued)
Type Drug Target Gene Gene
P-value
Class
Resveratrol NQO2
CSNK2A1
PTGS1/2
ALOX5/15
AHR
PI4K2B
ITGA5
ITGB3
APP
ESR1
MTNR1A/1B
CLEC14A
NR1I2/3
SLC2A1
SNCA
CBR1
PPARA
PPARG
AKT1
KHSRP
YARS
APOA1
BACE1
SCN5A
SIRT1
TXNRD1/D2
XDH
MAOA
0.97
0.29
0.43
0.06
0.75
0.99
0.44
0.51
0.08
0.13
0.20
0.93
0.16
0.77
0.91
0.67
0.97
0.72
0.26
0.64
0.91
0.27
0.25
0.82
0.71
0.75
0.56
--
Anti-inflammation (herpes simplex virus)
Acetyl-L-Carnitine Nil – Other (fatty acyls)
Angiotensin II receptor blocker +
calcium channel blocker
AGTR1
CACNA1B/1C
CACNA1D/1S
CACNA2D1/D3
CACNB1/B2
CA1
SMPD1
0.97
0.83
0.03
0.98
0.05
0.35
0.96
Anti-hypertensives
Choline alfoscerate GM2A 0.63 Other (glycerophosphocholines)
Ginkgo biloba SLC6A2
PLA2G2A
GLRA1
GABRA1
GABRB2
GABRG2
0.06
0.90
0.57
0.45
0.81
0.96
Other (possibly improving blood flow)
Octohydroaminoacridine Succinate Nil – Acetylcholinesterase inhibitor
a Source: Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/), Drugbank (https://www.drugbank.ca/) and Drug Repurposing Hub (https://clue.io/
repurposing) as of August 30, 2018.
b Source: ClinicalTrial.gov (https://clinicaltrials.gov/), Cummings J, et al. (2016) Alzheimer's & Dementia: Translational Research & Clinical Interventions (http://www.trci.alzdem.com/
article/S2352-8737(16)30019-1/pdf) andAlzForum(http://www.alzforum.org/therapeutics). The list of investigational drugswas based ondrugs being tested in recruiting or active Phase
III or IV trials registered in ClinicalTrial.gov or listed in AlzForum as of January 28, 2018, supplemented by drugs in Phase III trials listed in Cummings J, et al. (2016), excluding diagnostic
drugs and drugs for sequelae of AD, such as for agitation or sleep disorders.
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by a Mendelian randomization study on apolipoprotein E [4], which
has long been considered as a drug target [47]. Recently, APOE ε4 al-
leles have been shown to promote a gain of toxic effects by indepen-
dently promoting Aβ and tau protein production in human neurons
[41]. Taken together with the null findings from randomized con-
trolled trials of statin on cognitive functions [48] and Mendelian
randomization studies of low-density lipoprotein cholesterol [49]
and triglyceride [50] on late-onset AD, better understanding on
the functionality of both gene and gene clusters would add more
nuanced mechanistic insights on lipid metabolism e.g. apolipopro-
tein E as a cholesterol transport protein may be more relevant
than cholesterol synthesizing proteins.
Importantly, this study identified products of 11 late-onset AD
genes that are currently targeted by other therapies [51–53] that
could possibly be further investigated to clarify the disease genetics
and drug actions before repurposing for late-onset AD. Gemtuzumab
ozogamicin, which targets CD33 gene products, is an approved treat-
ment for acute myeloid leukemia and has been considered for re-
purposing in AD [54]. Omalizumab, which targetsMS4A2 gene prod-
ucts and another gene (FCER1A), is a subcutaneous injectable con-
trolling moderate-to-severe allergic asthma; Leflunomide, which
targets PTK2B gene products in addition to 2 other genes (AHR,
PTK2B), is an orally-administered immunosuppressive disease-
modifying anti-rheumatic drug. These existing drugs already have
phase II trial results such that pharmacodynamics, pharmacokinet-
ics, toxicity, preclinical effects in vitro and in vivo and phase I safety
and dosage results are known, which reduces the risk, time and re-
sources needed for possible drug re-purposing after more scrutiny
of their relevance to AD.
Our findings provide an initial step in translating AD genetics to
therapeutic targets and should be enriched using network medicine
by characterizing any drug actions within biological networks.
Given many diseases including late-onset AD may be related to
functional disruption of multiple genes rather than single genes
and these genes may cluster and interact as disease modules, net-
work medicine may help integrate regulatory networks, RNA net-
works, protein-protein interactions and metabolic pathways to
delineate the complex links from disease genes to drug targets
[55]. Moreover, disease proximity and similarity between two dif-
ferent drugs might indicate shared mechanisms between two dis-
eases with implications for drug re-purposing [56]. Drugs may
target specific but not entire disease modules [56] and may partly
inhibit or activate interactions and functions [57], thereby AD
drug targets are not necessarily the products of AD genes. In addi-
tion, only a fraction of proteins (gene products) can be manipulated
by small molecule drugs [57]. Clarifying the direction of drug ac-
tions as well as the drug effects within integrated biological net-
works would help identify gene products as druggable targets. As
such, building and integrating drug-drug relationships, gene-
protein interactions, and disease-disease networks may provide a
framework for further identifying drug targets [58]. Further, the
use of computational drug-target interactions may help predict
druggability by integrating genomics, pharmacological properties,
biochemical interactions supplemented with similarities between
drugs and target proteins [59]. Although the network-based analyt-
ical techniques are evolving and the interactome and drug-protein
interactions remain to be fully understood, to date, network-based
analysis using GWAS data has contributed in prioritizing disease
genes by mapping candidate genes within the protein-protein in-
teraction network [60] supplemented by further searches of sub-
networks [61]. Specifically for AD, Talwar et al. (2014) found 6
gene clusters related to 7 proteins encoded by genes EGFR, ACTB,
CDC2, IRAK1, APOE, ABCA1, AMPH with EGFR and ACTB as key genes
[62]. Browne et al. (2015) found 32 prioritized AD genes with
Table 3
Genes strongly associated with late-onset Alzheimer's disease with products targeted by
existing drugsa.
Drug Target
Gene
Gene
P-value
Class
Afatinib HBEGF 1.83 × 10−06 Anti-cancer EGFR
inhibitors
Brigatinib
Cetuximab
Erlotinib
Gefitinib
Lapatinib
Necitumumab
Neratinib
Olmutinib
Osimertinib
Panitumumab
Glatiramer acetate HLA-DQA1 9.36 × 10−07 Immunomodulator for
multiple sclerosis
Apolizumab HLA-DRB1 8.77 × 10−05 Anti-cancer
immunomodulator
Vandetanib EPHA1 7.57 × 10−10 Anti-thyroid cancer
EGFR, RET tyrosine,
VEGFR kinase inhibitors
Copper CLU 5.91 × 10−16 Metal compounds
Zinc
Zinc acetate
Zinc chloride
Baricitinib PTK2B 3.66 × 10−07 Anti-Rheumatoid JAK
inhibitor
Leflunomide
Omalizumab MS4A2 4.47 × 10−09 Anti-IgE for severe
allergic asthma
Alacepril ACE 0.01 Anti-hypertensive ACE
inhibitors
Benazepril
Benazeprilat
Captopril
Ceronapril
Cilazapril
Delapril
Deserpidine
Enalapril
Enalaprilat
Fosinopril
Fosinoprilat
Gemopatrilat
Imidapril
Indolapril hydrochloride
Libenzapril
Lisinopril
Moexipril
Pentopril
Perindopril
Pivopril
Quinapril
Quinaprilat
Ramipril
Rescinnamine
Spirapril
Spiraprilat
Temocapril
Trandolapril
Zofenopril
Zofenoprilat arginine
Copper APOE 0 Metal compounds
Zinc
Zinc acetate
Zinc chloride
Gemtuzumab ozogamicin CD33 8.09 × 10−07 Treatment for acute
myleoid leukemia
Curcumin APP 0.08 Nutraceuticals extracted
from tumeric
a Source: Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/
kegg/), Drugbank (https://www.drugbank.ca/) and Drug Repurposing Hub (https://clue.
io/repurposing) as of August 30, 2018.
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PSEN1 and TRAF1 as key genes [63]. Both studies identified AD genes
primarily related to neurogenesis and its regulation based on func-
tional annotation using gene-ontology [62,63]. Hu et al. (2017)
found 3 main modules related to neuronal pathways and metabo-
lism, cell growth or survival and neuroendocrine, and immune re-
sponse using pathway crosstalk analysis [64]. Given these
previous studies only considered AD genes as a whole, our system-
atically identified late-onset AD genes could be utilized for late-
onset AD-related gene cluster identification and functional annota-
tion. Mostafavi et al. (2018) found INPPL1 and PLXNB1 related to
late-onset AD using RNA sequencing from a cohort of 478 older
adults with brain autopsy [65]. While these previous network-
based studies do not replicate in their most relevant genes, two of
these genes (ABCA1, INPPL1) are paralog of genes identified in our
study (ABCA7, INPPD5). Alternatively, comparison of gene expres-
sion profiles and drug-induced RNA expression profiles could pro-
vide further insights to connect genes to existing drugs [66,67].
Issa et al. (2016) found several approved or experimental drugs
(such as Rasagiline, Interferons, Calcium, Dovitinib, Somatropin Re-
combinant) related to AD [68]. Vargas et al. (2018) found 6 ap-
proved drugs (Cefuroxime, Cyproterone, Dydrogesterone,
Metrizamide, Trimethadione, Vorinostat) negatively associated
with AD [69]. Both studies used disease-related gene expression
from the Gene Expression Omnibus (GEO) database, but applied to
different drug-induced expression profiles, which might account
for the differences in the identified drugs [68,69]. The late-onset
AD genes and existing drugs for other indications identified in this
study would allow more refined comparison of expression profiles
in future studies for drug repurposing, of which timely evidence is
needed considering this study identified that current approved
and investigational AD drugs may not be targeting late-onset AD
genes.
This systematic and agnostic identification of genes for late-onset
AD provides directions for re-thinking AD treatments. Nevertheless,
several limitations are noted. First, the genes identified here from
IGAP relate to late-onset AD. As such, they may not be relevant to
early-onset AD, i.e., AD occurring before the age of 65 years, which
may explain the non-identification of the 3 genes (APP, PSEN1,
PSEN2) associated with early-onset AD [36]. Although a rare variant
of APP might be related to late-onset AD as well, but is likely
context-specific as it has been found in Nordic countries whereas it
is very rare in the United States [37]. Second, the genes identified
might not be a complete set and did not include genes on the sex
chromosomes. Replication of the gene-based test in a different pop-
ulation or using a future GWAS with a larger sample size may reveal
additional genetic targets. The recent trans-ethnic GWAS for AD
using a gene-based test with the same GATES method identified 8
late-onset AD genes, of which nearly all genes (CR1, BIN1, PTK2B,
CLU, PICALM, and ABCA7) were also identified in our study. The only
new gene (TPBG) that study identified was neither found in the pre-
vious GWAS of European ancestry [26] nor reached genome-wide
significance in their European ancestry-specific result [23], indicat-
ing the relevance of certain genesmay be population-specific. Never-
theless, consistency in genes identified in both trans-ethnic GWAS
and our study with a larger sample size and greater power without
excluding SNPs with P-valueb1 × 10−5 lends credence to the gene-
based association approach. Third, this study aims to identify poten-
tial genetically validated drug targets rather thanmap out the full ge-
netic functionality or pathophysiology of these targets, because re-
purposing therapies acting on genetically validated targets may be
the swiftest way of developing effective new treatments. We ac-
knowledge that the current gene-based analysis might not provide
comprehensive therapeutic effects and AD pathogenesis. Comparing
disease gene-related and drug-induced gene expression profiles may
provide further insights [66]. Fourth, our identified drug targets de-
pend on the validity and completeness of KEGG, Drugbank and
Drug Repurposing Hub. While the Drug Repurposing Hub incorpo-
rates extensive in-house drug target data, more publicly available
data from pharmaceutical companies would make the search more
comprehensive especially for investigational drugs [70]. Moreover,
these curated cross-references are constantly beingmademore com-
prehensive to reflect new discoveries, so it is possible that new tar-
gets will be found in the future. Fifth, some valid targets of existing
drugs might not reach genome wide significance. For example the
gene related to statins (HMGCR) [71] is only nominally (P-value =
.004) associated with ischemic heart disease [72]. Sixth, the gene-
based test considers SNPs within or near the genes using the same
amount of SNPs as the SNP-based GWAS, but not intergenic regions
[33]. Our findings can be supplemented by future studies identifying
SNPs outside of genes associated with late-onset AD to provide a
comprehensive AD genome. Seventh, this study considers genes re-
ported based on index SNPs to allow comparison with previous AD
GWAS [26]. However, SNP-based GWAS identifies genomic regions
(loci) which may correspond to multiple genes that do not necessar-
ily correspond to the genes implicated in late-onset AD [73]. Consid-
eration of multiple genes within the loci given in a recent review of
GWAS of late-onset AD [73] identified 4 more genes (HLA-DQA1,
MS4A4A, MS4A6E, MS4A2) using both approaches. Our gene based
test identified 35 genes not found by previous SNP-based GWAS. Fi-
nally, case-control studies of older people are inevitably open to se-
lection bias, meaning that genes lethal for other diseases may
appear relevant to late-onset diseases [74]. However, the genes we
identified are not associated with major diseases that may result in
death before the onset of AD, such as ischemic heart disease [72] or
stroke [75].
In conclusion, our study provides no evidence that approved and in-
vestigational AD drugs are targeting products of genes strongly associ-
ated with late-onset AD, which might explain the lack of efficacy to
date. Genetic validation of potential AD drugs might help to identify
the most promising drugs to try to combat AD, conversely a gene-
based test may also provide an initial screening tool to identify drugs
that are unlikely to be successful. Other drugs targeting products of
late-onset AD genes do already exist, but themechanisms of disease ge-
netics and drug actions need further clarification before proposing drug
targets to combat late-onset AD.
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